Stay updated on Tipifarnib in HRAS-Mutant Squamous Head and Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Tipifarnib in HRAS-Mutant Squamous Head and Neck Cancer Clinical Trial page.

Latest updates to the Tipifarnib in HRAS-Mutant Squamous Head and Neck Cancer Clinical Trial page
- Check3 days agoChange DetectedA site-wide government funding status notice has been added and the site revision updated from v3.4.0 to v3.4.1.SummaryDifference0.3%

- Check10 days agoChange DetectedGlossary toggle added and metadata labels updated (QC criteria status wording and revision version). These are administrative updates that do not alter core study content, eligibility, or results.SummaryDifference0.2%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check46 days agoChange DetectedIntroduced a consolidated Locations section listing multiple sites across the United States and England, replacing the previous state-specific location entries.SummaryDifference0.9%

- Check74 days agoChange DetectedPublications section now states that publications are automatically filled from PubMed, and a Revision: v3.3.2 tag was added; the previous PubMed description and Revision: v3.2.0 tag were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check81 days agoChange DetectedNotice about government funding lapse and NIH operating status was removed. The previous notice informed users that information may not be up to date and directed users to cc.nih.gov and opm.gov for status updates.SummaryDifference0.3%

Stay in the know with updates to Tipifarnib in HRAS-Mutant Squamous Head and Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tipifarnib in HRAS-Mutant Squamous Head and Neck Cancer Clinical Trial page.